Implantable Defibrillators Market by Product Type [Transvenous Implantable Cardioverter-Defibrillator, Subcutaneous Implantable Cardioverter Defibrillators, and Cardiac Resynchronization Therapy Defibrillator]: Global Opportunity Analysis and Industry Forecast, 2020-2030″ report has been added to ResearchAndMarkets.com’s offering.
The global implantable defibrillators market was valued at $3,300.00 million in 2020, and is projected to reach $5,612.62 million by 2030, registering a CAGR of 5.3% from 2021 to 2030.
Implantable cardioverter defibrillators (ICDs) are devices used to treat patients with heart arrhythmias that occur in the heart’s lower chambers or ventricles, which can be life threatening.
ICDs are typically implanted in patients who have a weakened heart, owing to a history of heart blockages and/or heart attacks or in those with heart muscle tissue that are enlarged or thickened. Occasionally, ICDs are implanted in patients who have an inherited heart defect that makes their heart beat abnormally.
Implantable cardioverter defibrillator (ICD) is an equipment or device implanted inside the human body to perform cardioversion, correct pacing, and defibrillation of the heart. The product is generally used in treating sudden cardiac arrest owing to ventricular fibrillation, cardiac arrhythmias, and pulseless ventricular tachycardia.
Implantable defibrillators are battery-powered small devices placed underneath the chest or abdomen to keep track of a patient’s heart rate. Increase in palpitation is diagnosed by the device and the normal heart rhythm is restored. These devices play a vital role in preventing sudden cardiac arrest in patients who suffer from sustained ventricular tachycardia or atrial fibrillation. Therefore, ICDs constantly monitor the heart rhythm through electrodes and deliver treatments when an abnormal heart rhythm is detected. The treatments through ICDs include pacing, cardioversion, and defibrillation to restore a normal heart rhythm.
The growth of the implantable defibrillators market is attributed to advancements in technology such as introduction of quadripolar lead devices to improve device programming, extend battery life, and development of magnetic resonance imaging (MRI)-safe ICDs. In addition, a rise in the incidence of atrial fibrillation and the high risk of a sudden cardiac arrest (SCA) fuel the demand for implantable defibrillator devices.
Furthermore, introduction of subcutaneous ICD technology in 2012 has revolutionized the treatment technology for cardiac rhythm management through these devices. Boston Scientific’s S-ICDs were granted the market clearance in 2012, which was the first commercially available S-ICDs system worldwide. S-ICDs are widely adopted, as they are implanted below the skin without the leads to be placed inside the heart. This fueled the demand for S-ICDs globally, thus driving the growth of the market. However, the presence of alternative treatment and limited insurance coverage are projected to hamper the market growth.
The major players operating in the global Implantable Defibrillators market are Abbott, Biotronik SE & Co. KG, Boston Scientific Corporation, Fukuda Denshi Co. Ltd., Imricor Medical Systems, Koninklijke Philips N.V., LivaNova Plc Company, Medtronic Plc, Microport scientific corporation, and Nihon Kohden Corporation. These players adopted product launch, collaboration, and merger & acquisition as their key developmental strategies.
Key Benefits
- The report provides in-depth analysis of the global Implantable Defibrillators market size along with the current trends and future estimations to elucidate the imminent investment pockets
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Implantable Defibrillators market growth
Key Topics Covered:
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter’s Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power Among Buyers
3.4. Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Covid-19 Impact Analysis
Chapter 4: Implantable Defibrillators Market, by Product Type
4.1. Market Overview
4.1.1Market Size and Forecast, by Product Type
4.2. Transvenous Implantable Cardioverter-Defibrillator (T-Icds)
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Share Analysis, by Country
4.3. Subcutaneous Implantable Cardioverter Defibrillators (S-Icds)
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Share Analysis, by Country
4.4. Cardiac Resynchronization Therapy Defibrillator (Crt-D)
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Share Analysis, by Country
Chapter 5: Implantable Defibrillators Market, by Region
Chapter 6: Company Profiles
6.1. Abbott Laboratories
6.1.1. Company Overview
6.1.2. Key Executives
6.1.3. Company Snapshot
6.1.4. Operating Business Segments
6.1.5. Product Portfolio
6.1.6. Business Performance
6.1.7. Key Strategic Moves and Developments
6.2. Biotronik Schweiz AG
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Company Snapshot
6.2.4. Operating Business Segments
6.2.5. Product Portfolio
6.2.6. Business Performance
6.2.7. Key Strategic Moves and Developments
6.3. Boston Scientific Corporation
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Company Snapshot
6.3.4. Operating Business Segments
6.3.5. Product Portfolio
6.3.6. Business Performance
6.3.7. Key Strategic Moves and Developments
6.4. Fukuda Denshi Co. Ltd
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Company Snapshot
6.4.4. Operating Business Segments
6.4.5. Product Portfolio
6.4.6. Business Performance
6.4.7. Key Strategic Moves and Developments
6.5. Imricor Medical Systems
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Company Snapshot
6.5.4. Operating Business Segments
6.5.5. Product Portfolio
6.5.6. Business Performance
6.5.7. Key Strategic Moves and Developments
6.6. Koninklijke Philips N. V.
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Company Snapshot
6.6.4. Operating Business Segments
6.6.5. Product Portfolio
6.6.6. Business Performance
6.6.7. Key Strategic Moves and Developments
6.7. Livanova plc
6.7.1. Company Overview
6.7.2. Key Executives
6.7.3. Company Snapshot
6.7.4. Operating Business Segments
6.7.5. Product Portfolio
6.7.6. Business Performance
6.7.7. Key Strategic Moves and Developments
6.8. Medtronic plc.
6.8.1. Company Overview
6.8.2. Key Executives
6.8.3. Company Snapshot
6.8.4. Operating Business Segments
6.8.5. Product Portfolio
6.8.6. Business Performance
6.8.7. Key Strategic Moves and Developments
6.9. Microport Scientific Corp
6.9.1. Company Overview
6.9.2. Key Executives
6.9.3. Company Snapshot
6.9.4. Operating Business Segments
6.9.5. Product Portfolio
6.9.6. Business Performance
6.9.7. Key Strategic Moves and Developments
6.10. Nohen Kohden Corporation
6.10.1. Company Overview
6.10.2. Key Executives
6.10.3. Company Snapshot
6.10.4. Operating Business Segments
6.10.5. Product Portfolio
6.10.6. Business Performance
6.10.7. Key Strategic Moves and Developments
For more information about this report visit here.